Treatment Sustains Clinical Benefit Over Two Years in R/R CLL, SLL
Liso-cel shows durable efficacy in R/R CLL/SLL, with extended OS of 43.2 months, high uMRD rates, and consistent safety after nearly two years of follow-up.
Jan 22, 2025
MEETING BRIEF
ASH 2024 – CLL/SLL
The latest news from ASH 2024 focused on chronic lymphocytic leukemia (CLL) including abstracts, features, and helpful conference information.
Assessing QOL and Treatment Impact in Asymptomatic Early-Stage CLL
Assessing QOL and Treatment Impact in Asymptomatic Early-Stage CLL
The CLL 12 study found ibrutinib improved global health/physical function without overall survival benefits in early-stage, asymptomatic CLL.
Treatment Combo Provides Consistently High PFS in CLL, SLL
Treatment Combo Provides Consistently High PFS in CLL, SLL
First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.
Q&A: The Vital Role of Nurses & APs in Enhancing Palliative Care for Patients With Blood Cancer Undergoing Transplant
Q&A: The Vital Role of Nurses & APs in Enhancing Palliative Care for Patients With Blood Cancer Undergoing Transplant
Physician's Weekly spoke with Richard Newcomb, MD, on the role of nurses and APs in enhancing palliative care.
Challenges in Treating Richter Transformation with Novel Agents
Challenges in Treating Richter Transformation with Novel Agents
A recent study from ASH 2024 examined the clinical features and outcomes of RT in British Columbia, comparing two eras: the chemoimmunotherapy (CIT) era (pre-2016) and the novel agents (NA) era (post-2016).
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
